新闻通稿

/新闻通稿

Oramed to Present at the Disruptive Growth Showcase Conference

JERUSALEM, Sept. 25, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming 2017 Disruptive Growth Company Showcase NYC Conference, taking place September [...]

2017-09-25T08:56:52+00:00 Categories: 新闻通稿|Tags: |

Oramed Announces Successful Meeting with FDA for Oral Insulin

JERUSALEM, Sept. 5, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has successfully concluded its meeting with the U.S. Food and Drug Administration (FDA) regarding ORMD-0801, [...]

2017-09-05T06:01:09+00:00 Categories: 新闻通稿|Tags: |

Oramed to Present at the Rodman & Renshaw Global Investment Conference

JERUSALEM, August 29, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming Rodman & Renshaw 19th Annual Global Investment Conference, taking place [...]

2017-08-29T08:50:48+00:00 Categories: 新闻通稿|Tags: |

Oramed to Present at BIT’S 5th World Congress of Diabetes on July 13, 2017

JERUSALEM, July 12, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Dr. Miriam Kidron, Oramed's Chief Scientific Officer, will deliver a presentation titled, "Oral Insulin for Diabetes Treatment: [...]

2017-07-12T08:51:22+00:00 Categories: 新闻通稿|Tags: |

Oramed Announces Dual-Listing on Tel Aviv Stock Exchange

JERUSALEM, July 5, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has received approval from the Israel Securities Authority to dual-list its common stock on the Tel [...]

2017-07-05T08:50:08+00:00 Categories: 新闻通稿|Tags: |

Oramed to Present at the American Diabetes Association 77th Scientific Sessions

JERUSALEM, June 6, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing the recent Phase IIb study of its orally ingestible insulin capsule, ORMD-0801, will be presented [...]

2017-06-06T08:45:44+00:00 Categories: 新闻通稿|Tags: |

Oramed to Present at Conferences Next Week

JERUSALEM, May 18, 2017 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that  Chief Executive Officer, Nadav Kidron, will present at three conferences next week in Tel Aviv, Israel.  Oppenheimer's 17th [...]

2017-05-18T08:45:31+00:00 Categories: 新闻通稿|Tags: |